Biotech | January 24, 2022
USFDA approves IND application for Allied’s cancer treatment
APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types
APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types
It is indicated for the treatment of patients with acromegaly and Gastroenteropancreatic Neuroendocrine Tumours
Whipple procedure is a very complex operation, mainly performed to remove pancreatic cancer
The rise in cases amongst the young is a cause for concern. A few specialists gave us a perspective on the issue
The release of this batch will secure the supply for hospitals and cancer centres that are involved in the clinical trials managed by the company
The first patient dosed with VX-880 demonstrated restoration of insulin production and achieved C-peptide of 560 pmol/L in response to Mixed Meal Tolerance Test (MMTT) at Day 90 visit
_256_384.png){kind=logo}
Results from these studies are expected to be released by 2023. If outcomes from these initial pilots are positive, the studies will be expanded to involve around 1 million participants in 2024 and 2025
The medicine is now approved for eight indications across five different types of cancer in China.
The company’s RenovoCath Delivery System designed for targeted treatment of solid tumours
The drug is also intended for the treatment of glioblastoma multiforme
Subscribe To Our Newsletter & Stay Updated
